Quick Answer
Amneal Pharmaceuticals, Inc. reported R&D Expense of $186.18 million for fiscal year 2025.
Amneal Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $186.18M | -2.4% |
| 2024 | $190.71M | +16.3% |
| 2023 | $163.95M | -16.2% |
| 2022 | $195.69M | -3.1% |
| 2021 | $201.85M | +12.2% |
| 2020 | $179.93M | -4.3% |
| 2019 | $188.05M | -3.2% |
| 2018 | $194.19M | +13.3% |
| 2017 | $171.42M | -4.2% |
| 2016 | $179.02M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $63.35M | +3.7% | +32.1% |
| June 30, 2025 | $47.96M | +33.0% | +19.8% |
| March 31, 2025 | $40.04M | +1.9% | -34.5% |
| September 30, 2024 | $61.10M | +47.7% | +69.5% |
| June 30, 2024 | $36.05M | -4.6% | -8.3% |
| March 31, 2024 | $39.30M | +1.6% | -5.0% |
| September 30, 2023 | $41.38M | -17.6% | +9.5% |
| June 30, 2023 | $37.80M | -25.5% | -2.3% |
- Amneal Pharmaceuticals, Inc. showed a decrease of -2.4% in R&D Expense compared to the prior fiscal year.
- Over the 2016–2025 period, Amneal Pharmaceuticals, Inc.’s r&d expense has grown by 4.0% (from $179.02 million to $186.18 million).
- The most recent figure is from Amneal Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: